- Home
- ALNY vs CSGP Comparison
ALNY vs CSGP Comparison
Compare ALNY & CSGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- CSGP
- Stock Information
- Founded
- ALNY 2002
- CSGP 1987
- Country
- ALNY United States
- CSGP United States
- Employees
- ALNY N/A
- CSGP N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- CSGP Business Services
- Sector
- ALNY Health Care
- CSGP Consumer Discretionary
- Exchange
- ALNY Nasdaq
- CSGP Nasdaq
- Market Cap
- ALNY 35.0B
- CSGP 33.4B
- IPO Year
- ALNY 2004
- CSGP 1998
- Fundamental
- Price
- ALNY $251.15
- CSGP $74.57
- Analyst Decision
- ALNY Strong Buy
- CSGP Buy
- Analyst Count
- ALNY 25
- CSGP 14
- Target Price
- ALNY $324.54
- CSGP $88.43
- AVG Volume (30 Days)
- ALNY 972.8K
- CSGP 3.4M
- Earning Date
- ALNY 05-01-2025
- CSGP 04-29-2025
- Dividend Yield
- ALNY N/A
- CSGP N/A
- EPS Growth
- ALNY N/A
- CSGP N/A
- EPS
- ALNY N/A
- CSGP 0.28
- Revenue
- ALNY $2,348,099,000.00
- CSGP $2,812,000,000.00
- Revenue This Year
- ALNY $31.88
- CSGP $17.61
- Revenue Next Year
- ALNY $25.06
- CSGP $10.97
- P/E Ratio
- ALNY N/A
- CSGP $267.04
- Revenue Growth
- ALNY 17.21
- CSGP 11.28
- 52 Week Low
- ALNY $144.73
- CSGP $68.26
- 52 Week High
- ALNY $304.39
- CSGP $92.74
- Technical
- Relative Strength Index (RSI)
- ALNY 48.55
- CSGP 42.97
- Support Level
- ALNY $245.96
- CSGP $74.02
- Resistance Level
- ALNY $277.85
- CSGP $76.89
- Average True Range (ATR)
- ALNY 10.60
- CSGP 2.49
- MACD
- ALNY 1.41
- CSGP -0.64
- Stochastic Oscillator
- ALNY 42.07
- CSGP 6.47
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About CSGP CoStar Group Inc.
CoStar Group is a leading provider of commercial real estate data and marketplace listing platforms. Its data offering contains in-depth analytical information on over 5 million commercial real estate properties related to various subsectors including office, retail, hotels, multifamily, healthcare, industrial, self-storage, and data centers. It operates many flagship brands such as CoStar Suite, LoopNet, Apartments.com, BizBuySell, and Lands of America, with more than 80% of its revenue classified as subscription-based. The company recently expanded its presence in Canada, the United Kingdom, Spain, and France.